Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04735666

European TauroPace Registry - University of Schleswig-Holstein Prospective Observational Clinical Study

University of Schleswig-Holstein Campus Kiel is sponsoring the European TauroPace Registry. This investigator-initiated local, prospective, non-interventional, multi-center study includes patients undergoing cardiac implantable electronic placement including and not limited to placement, revision with the aim to upgrade or downgrade, generator substitution, additional lead placement, revision or extraction (procedure) with adjunct TauroPace. It is planned to include a total of at least 2300 procedures (valid for safety analysis).

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Landeskrankenhaus Wiener Neustadt, Wiener Neustadt, Austria

Loading trial locations.

About this study

This study is performed as an all-case investigation. The treatment is performed based on the SOPs (Appendix Study Protocol). The standard observation period is 3 months from the 1st treatment. Safety and effectiveness are evaluated at 3rd and 12th month. In addition, the extension observation is carried out once a year for 3 years at the longest to collect information on safety and effectiveness as long as CIED treatment continues. When the treatment ends (extraction of all hardware), observation of a patient ends. For each patient, the investigator records data as defined in the protocol at each evaluation point by using a unique Case Report Form (CRF) system. The duration of the study is estimated at 10 years (registry).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Use of TauroPace™ is indicated and not contra-indicated according to its current Instructions For Use (IFU)
  • Participant is eligible for a CIED related surgery procedure.

Exclusion criteria

  • Age<18years
  • Participant incapable of signing Patient Informed Consent (mentally or physically) or does not sign.

Treatment and study plan

TauroPace™

Device

TauroPace™ is intended to be used as a disinfecting solution during any CIED related surgery procedure or handling of any uncoated or silicon-, epoxy- or polyurethane-coated CIED (including its components, e.g., leads) made of titan or stainless steel in any adult patient requiring or carrying a CIED.

Primary outcomes

  1. CIED infections

    Time frame: three months

    CIED infections occurring in an observation period of three months after any CIED related surgical procedure in different CIED using a regimen with surface disinfection of CIEDs and irrigation of the surgical site (pocket) with a taurolidine containing antimicrobial compound adjunct.

Secondary outcomes

  1. CIED infections

    Time frame: 12 months

    CIED infections occurring in an observation period of 12 months after any CIED related surgical procedure in different CIED using a regimen with surface disinfection of CIEDs and irrigation of the surgical site (pocket) with a taurolidine containing antimicrobial compound adjunct.

  2. CIED infections

    Time frame: 36 months

    CIED infections occurring in an observation period of 36 months after any CIED related surgical procedure in different CIED using a regimen with surface disinfection of CIEDs and irrigation of the surgical site (pocket) with a taurolidine containing antimicrobial compound adjunct.

  3. AE

    Time frame: 3, 12 and 36 months

    Adverse events (complications) during 3, 12 and 36 months follow-up

  4. All-cause mortality

    Time frame: 3, 12 and 36 months

    Allcause mortality during 3, 12 and 36 months follow-up

Sponsors and collaborators

Lead sponsor

University of Kiel

Other

Collaborators

  • University of Luebeck

Registry information

Acronym: ETPR

Important dates

Study start
2021
Primary completion
2030
Study completion
2030
First posted
Feb 3, 2021
Registry last updated
May 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.